ClinicalTrials.gov
public full text
Public Domain
The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia
The primary objective of this project is to examine the effects of varenicline treatment used concomitantly with antipsychotic medications, on cognitive dysfunction in people with schizophrenia. The secondary objective is to evaluate the effect of this combination therapy on smoking in people with schizophrenia. This study will be a randomized, double blind, parallel group, placebo controlled 8 weeks trial.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors#1093608
- Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment#867529
- Study of the Effects of Mecamylamine and Varenicline in Schizophrenia#899678
- Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia#902582
- tDCS and Cognitive Training Intervention for Chronic Smokers With Schizophrenia#992905
Record · ID 875471
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive